



JAGSONPAL PHARMACEUTICALS LIMITED

Regd. office : T-210 J, Shahpur Jat, New Delhi-110 049 (INDIA)

Fax : 0091-11-26498341,26494708, Phone: 0091-11-26494519-24

E-mail: admin@jagsonpal.com

Audited Financial Results for the Quarter ended 31.03.2010

(Rs. in lacs)

Particulars	Quarter ended	Quarter ended	12 Months ended	12 Months ended
	31.03.2010 Audited	31.03.2009 Audited	31.03.2010 Audited	31.03.2009 Audited
1(a) Net sales/Income from Operations	3957.76	3235.16	13959.34	13619.76
1(b) Other Operating Income				
Total	3957.76	3235.16	13959.34	13619.76
2 Expenditure				
a. (Inc.)/Dec. in Stock in trade and work in progress	-231.38	-401.28	-1042.09	787.24
b. Consumption of Raw Materials	2430.44	2086.41	7219.40	6338.40
c. Purchase of traded goods	20.01	133.91	1372.92	764.68
d. Employees Cost	604.09	485.53	2378.78	1969.07
e. Depreciation	58.62	27.49	208.50	124.98
f. Other Expenditure	627.02	529.32	2458.50	2214.67
g. Total	3508.80	2861.38	12596.01	12199.04
3 Profit from Operations before Other Income, Interest and Exceptional Items (1-2)	448.96	373.78	1363.33	1420.72
4 Other Income	36.30	27.06	36.30	27.06
5 Profit before Int.& Exceptional Items (3+4)	485.26	400.84	1399.63	1447.78
6 Interest	93.88	114.06	349.62	457.93
7 Profit After Interest but before Exceptional items (5 - 6)	391.38	286.78	1050.01	989.85
8 Exceptional Items				
9 Profit(+)/Loss(-) from Ordinary Activities before tax (7 +8)	391.38	286.78	1050.01	989.85
10 Tax expense	25.81	175.62	125.81	372.62
11 Net Profit(+)/Loss(-) from Ordinary Activities after tax (9-10)	365.57	111.16	924.20	617.23
12 Extraordinary Items (net of tax expense)				
13 Net Profit (+)/ Loss (-) for the period (11-12)	365.57	111.16	924.20	617.23
14 Paid up Eq. Sh. Cap.(Face value Rs. 5)	1309.90	1309.90	1309.90	1309.90
15 Reserves excluding Revaluation reserves as per Balance sheet of pr. accounting yr.			6049.30	5277.85
16 Earnings Per Share (EPS)				
a. Basic & diluted EPS before extraordinary items for the period.	1.40	0.42	3.53	2.36
b. Basic & diluted EPS after extraordinary items for the period.	1.40	0.42	3.53	2.36
17 Public shareholding :				
- Number of shares	8962360	8962360	8962360	8962360
- Percentage of Shareholding	34.21%	34.21%	34.21%	34.21%
18 Promoter and promoter group shareholding				
a. Pledged / Encumbered				
- Number of shares	-	-	-	-
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-
- Percentage of shares (as a % of the total share capital of the Company)	-	-	-	-
b. Non - encumbered				
- Number of shares	17235640	17235640	17235640	17235640
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%
- Percentage of shares (as a % of the total share capital of the Company)	65.79%	65.79%	65.79%	65.79%

Notes

- The Audited Financial Results for the Quarter ended 31.3.2010 have been reviewed by the Audit Committee. The Board of Directors has approved the financial Results at its meeting held on 13-8-2010
- No complaints were pending at the beginning/end of the quarter ended 31.3.2010. However 43 requests for change of address/dividend revaluation/Annual Reports etc. were received & promptly responded to during the quarter.
- The Company is operating only in the Pharmaceuticals segment and hence compliance has been made under AS-17.
- The net effect of the deferred taxation for the Quarter as per AS-22 has been taken.
- Previous Year Figures have been regrouped / rearranged where ever necessary.
- The Company commenced Commercial Production at its New Manufacturing Facility at Pantnagar, Distt. Udham Singh Nagar, Uttarakhand during April 2009.
- The Board has recommended a Dividend of Rs.0.50 per equity Share on 2,61,98,000 equity shares of Rs. 5/- each for the year 2009-10.

By Order of the Board
For Jagsonpal Pharmaceuticals Limited

Rajpal Singh Kochhar
Managing Director

Place : New Delhi
Date : 13.08.2010

